## CASE REPORT

# Atypical presentation and management of fibrodysplasia ossificans progressiva

André Grenho, Joana Arcângelo, Augusto Martins

#### SUMMARY

Centro Hospitalar de Lisboa Central EPE, Serviço de Ortopedia - Hospital de Curry Cabral, Lisboa, Portugal

**Correspondence to** André Grenho, andregrenho@gmail.com

Accepted 26 June 2017

We report a case of an 18-year-old woman, with bilateral acute inflammatory pain on the hip area, during the premenstrual period, and progressive increase in volume and rigidity of both hips. Bilateral exuberant soft tissue calcifications were present on the radiographic exams, and the patient also presented with bilateral short-length hallux valgus. A heterozygous mutation in the protein kinase domain of *ACVR1* gene was found, allowing the diagnosis of fibrodysplasia ossificans progressive. Due to the relation between the disease flares and the premenstrual period, the patient was put into a chemically induced amenorrhea, with no new inflammatory crises since.

This case illustrates the importance of an accurate diagnosis to prevent unnecessary diagnostic procedures, as well as the need to develop specific treatment strategies to address each patient's particular needs.

#### BACKGROUND

Fibrodysplasia ossificans progressiva (FOP) is a rare and incapacitating autosomal-dominant disease affecting connective tissue by defectively inducing endochondral osteogenesis.<sup>1</sup> Classical signs of this condition are hallux or thumb deformities and progressively debilitating heterotopic ossification, with normal bone formation in extraskeletal sites, such as soft tissues around the neck and shoulders.<sup>2</sup> Confusion with tumours is common, which may lead to aggressive and invasive diagnostic or excision techniques that will only accelerate the rate of bone growth.<sup>3</sup>

Atypical forms of FOP have also been described. These forms may present in two ways: classical FOP features in addition to one or more atypical features; or major variations of the two classically defining features.<sup>4</sup>

Managing this condition may be a challenge, and care must be taken to identify any trigger events that lead to soft tissue bone formation to develop a specific preventive strategy for each patient.



To cite: Grenho A, Arcângelo J, Martins A. *BMJ Case Rep* Published Online First: [*please include* Day Month Year]. doi:10.1136/ bcr-2017-221190

#### CASE PRESENTATION

We present an 18-year-old young woman, born from an incestuous relation, with prior history of oligophrenia, alopecia and bilateral hearing impairment. Patient was otherwise healthy until her menarche when she began experiencing acute inflammatory pain on the hip area during the premenstrual period, with progressive increase in volume and rigidity of both hips. She presented with a waddling gait, limited and painful mobility of both hips (0-0-75°) with hard and prominent bilateral masses (figure 1). There were no records of any traumatic events.

#### **INVESTIGATIONS**

Plain pelvic radiography (figure 2) and CT scan (figure 3) showed exuberant soft tissues calcifications, enveloping both hips and thighs. There was no involvement of the surrounding skeleton, and no other anomalous tissue was found on the calcifications location.

Patient was otherwise fit, with no recent history of weight loss, fever or other systemic signs of illness.

Due to these complaints, patient was referred to the orthopaedics consult for evaluation and to schedule a biopsy, as her family's physician suspected of a neoplastic lesion. However, due to the characteristics of the patient's feet (short hallux valgus with malformation of the first metatarsal) and of the anomalous masses, we considered there was a higher probability of FOP than of a malignant tumour.

Decision was made to send the patient for a genetics appointment, where a heterozygous mutation in the protein kinase domain of *ACVR1* gene, identified as the genetic cause of FOP, was found.

#### DIFFERENTIAL DIAGNOSIS Treatment

Due to the uncommon onset of these painful crises and a narrow correlation between the complaints and the premenstrual period, the case was discussed with the gynaecology department. Consideration was given to muscular endometriosis being the possible cause for the localised heterotopic endochondral bone formation. Unfortunately, no evidence was found supporting that theory, probably due to heterotopic bone formation preventing visualisation of any other anomalous tissues.

Given the contraindication for any invasive procedure, decision was made to chemically induce amenorrhea to control the inflammatory crises. Other usual measures for FOP were also taken, namely caretaker education for prevention of falls and other traumatisms, as well as usage of corticosteroids during a short time period and non-steroid anti-inflammatory drugs whenever pain occurred.

#### **OUTCOME AND FOLLOW-UP**

At 3 years' follow-up, no new painful crises have been reported, with the exception of two isolated traumatic events.

# **Rare disease**



**Figure 1** Anterior and posterior aspect of the patient's pelvis, at physical examination, with prominent bilateral masses in the hip area.

### DISCUSSION

FOP is a debilitating condition that usually displays its first symptoms by the first decade of life, with sporadic episodes of painful soft tissues swelling, usually triggered by trauma, muscle fatigue or influenza-like illnesses, promptly followed by bone formation.<sup>5</sup>

With a prevalence of one case in every two million people, this rare disease usually occurs as a new mutation in the protein kinase domain of *ACVR1* gene, leading to deregulation of specific bone morphogenetic proteins and destabilising connective tissue progenitor cells.<sup>67</sup>

FOP is often misdiagnosed by the untrained physician, and confused with conditions such as soft tissue sarcomas, even when classical clinical features are present. Aggressive and unnecessary diagnostic methods, such as biopsies, are commonly performed in these situations, leading not only to patient discomfort but also to an increase in local disease progression. Therefore, most authors advise against performing any surgical or invasive procedure in these patients.<sup>8</sup>

Identification of atypical forms of FOP, as the one depicted on this report, has important diagnostic and therapeutic implications. Kaplan *et al*<sup>4</sup> published a series of 12 atypical cases, some of which with a late onset, development of sparse thin hair and cognitive impairment. Although the inflammatory cascade plays a critical role in FOP,<sup>9</sup> our research retrieved no report of



**Figure 2** Plain pelvic radiography, showing bilateral calcified masses, around both hips.



**Figure 3** Axial images of CT scan, showing evidence of heterotopic soft tissue calcification, without any involvement of the surrounding skeleton (part figures A, B, C and D show the extension of the heterotopic calcification).

heterotopic ossification triggered by the inflammatory crises that may usually occur in the premenstrual period.

This case was a therapeutic challenge since there was no traumatic cause related to the disease flares that could be prevented. Nevertheless, a multidisciplinary approach was essential to come up with a definitive diagnosis and a therapeutic solution that provided successful control of the premenstrual inflammatory crises.

## Learning points

- Fibrodysplasia ossificans progressiva (FOP) is a debilitating condition that presents with endochondral osteogenesis of the soft tissues, usually following trauma or other conditions that trigger an inflammatory response.
- Biopsy of FOP lesions or other invasive procedures must be avoided at all costs, as they will lead to worsening of this disease.
- It is possible to partially control FOP with a strategy that addresses the specific trigger for the inflammatory response that leads to bone formation.

**Contributors** All authors contributed equally to patient's diagnostics, treatment and follow-up. AG and JA wrote the case report and AM was responsible for reviewing the manuscript.

Competing interests None declared.

Patient consent Obtained from guardian.

Provenance and peer review Not commissioned; externally peer reviewed.

© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

#### REFERENCES

- 1 Kaplan FS, McCluskey W, Hahn G, et al. Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J Bone Joint Surg Am 1993:75:1214–20.
- 2 Cohen RB, Hahn GV, Tabas JA, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 1993;75:215–9.
- 3 Kaplan FS, Tabas JA, Gannon FH, *et al*. The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. *J Bone Joint Surg Am* 1993;75:220–30.
- 4 Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. *Hum Mutat* 2009;30:379–90.

- 5 Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The natural history of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A comprehensive global Assessment. J Bone Miner Res 2016;31:650–6.
- 6 Billings PC, Fiori JL, Bentwood JL, et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008;23:305–13.
- 7 Shore EM, Xu M, Feldman GJ, *et al*. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat Genet* 2006;38:525–7.
- 8 Kitterman JA, Kantanie S, Rocke DM, et al. latrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. *Pediatrics* 2005;116:e654–e661.
- 9 Kaplan FS, Shen Q, Lounev V, et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab 2008;26:521–30.

Copyright 2017 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions.

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ► Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow